Tissue K+ in Primary Hyperaldosteronism

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Recent human studies found tissue sodium storage in patients with hyperaldosteronism that could be detected non-invasively by 23Na-MRI. Tissue sodium accumulation could be mobilized upon treatment of hyperaldosteronism. Besides, former animal studies applying chemical electrolyte analysis indicate that this aldosterone induced sodium storage might be accompanied by intracellular potassium loss. Wether such an intracellular tissue Potassium loss occurs in vivo in patients with hyperaldosteronism and if this deficiency can be corrected by treatment is unclear. The investigators will employ 39K-MR Imaging at 7Tesla to further assess this hypothesis.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Erlangen-Nürnberg Medical School
• Treatments: Eplerenone; Spironolactone

Criteria

Inclusion Criteria:

• Primary Hyperaldosteronism diagnosed according to the endocrinological guidelines (J Clin Endocrinol Metab, May 2016)

Exclusion Criteria:

• Chronic kidney disease stage 3b and below (estimated GFR <30 ml/min according to CKD-EPI)

• Acute kidney injury

• Severe congestive heart failure (NYHA III and IV)

• Liver Cirrhosis (Child B and C)

• Pregnancy

• Contraindications for MRI measurements: cardiac Pacemaker, claustrophobia, etc.